{"filing":{"accession_number":"0001835268-26-000027","cik":"0001835268","ticker":"CNTB","company_name":"Connect Biopharma Holdings Ltd","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"cntb-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1835268/000183526826000027/cntb-20260812.htm"},"events":[{"id":27208,"run_id":24781,"accession_number":"0001835268-26-000027","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a classic earnings release disclosure under Item 2.02. Connect Biopharma issued a press release on August 12, 2026 announcing financial results for the three and six months ended June 30, 2026, including cash position ($31.5 million), license and collaboration revenues ($2.8 million and $2.9 million for Q2 and H1 respectively), R\u0026D expenses ($16.3 million and $31.3 million), G\u0026A expenses ($4.1 million and $8.8 million), and net loss ($17.3 million and $36.7 million). The press release also provides material business updates on clinical trial milestones (completion of Phase 2 Seabreeze STAT enrollment) and cash runway expectations. This is material to investors as it discloses the company's financial condition and key operational progress.","company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28632,"accession_number":"0001835268-26-000027","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a classic earnings release disclosure under Item 2.02. Connect Biopharma issued a press release on August 12, 2026 announcing financial results for the three and six months ended June 30, 2026, including cash position ($31.5 million), license and collaboration revenues ($2.8 million and $2.9 million for Q2 and H1 respectively), R\u0026D expenses ($16.3 million and $31.3 million), G\u0026A expenses ($4.1 million and $8.8 million), and net loss ($17.3 million and $36.7 million). The press release also provides material business updates on clinical trial milestones (completion of Phase 2 Seabreeze STAT enrollment) and cash runway expectations. This is material to investors as it discloses the company's financial condition and key operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:17:08.757646+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28632,"accession_number":"0001835268-26-000027","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a classic earnings release disclosure under Item 2.02. Connect Biopharma issued a press release on August 12, 2026 announcing financial results for the three and six months ended June 30, 2026, including cash position ($31.5 million), license and collaboration revenues ($2.8 million and $2.9 million for Q2 and H1 respectively), R\u0026D expenses ($16.3 million and $31.3 million), G\u0026A expenses ($4.1 million and $8.8 million), and net loss ($17.3 million and $36.7 million). The press release also provides material business updates on clinical trial milestones (completion of Phase 2 Seabreeze STAT enrollment) and cash runway expectations. This is material to investors as it discloses the company's financial condition and key operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:17:08.757646+00:00","company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","filing_date":"2026-08-12"}]}